Cargando…

Thromboprofilaxys With Fondaparinux vs. Enoxaparin in Hospitalized COVID-19 Patients: A Multicenter Italian Observational Study

Importance: The use of anticoagulant therapy with heparins decreased mortality in hospitalized patients with severe coronavirus disease 2019 (COVID-19). Even if enoxaparin and fondaparinux have the same clinical indication for venous thromboembolism (VTE) prevention; to date, there are no data about...

Descripción completa

Detalles Bibliográficos
Autores principales:	Russo, Vincenzo, Cardillo, Giuseppe, Viggiano, Giuseppe Vito, Mangiacapra, Sara, Cavalli, Antonella, Fontanella, Andrea, Agrusta, Federica, Bellizzi, Annamaria, Amitrano, Maria, Iannuzzo, Mariateresa, Sacco, Clara, Lodigiani, Corrado, Castaldo, Giampiero, Di Micco, Pierpaolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7729125/ https://www.ncbi.nlm.nih.gov/pubmed/33330530 http://dx.doi.org/10.3389/fmed.2020.569567

Ejemplares similares

Antithrombotic and Anti-Inflammatory Effects of Fondaparinux and Enoxaparin in Hospitalized COVID-19 Patients: The FONDENOXAVID Study
por: Cardillo, Giuseppe, et al.
Publicado: (2021)

Fondaparinux and bleeding risk in COVID-19: unsolved question
por: Russo, Vincenzo, et al.
Publicado: (2021)

The Impact of Risk-Adjusted Heparin Regimens on the Outcome of Patients with COVID-19 Infection. A Prospective Cohort Study
por: Di Micco, Pierpaolo, et al.
Publicado: (2021)

Prognostic Value of Fibrinogen among COVID-19 Patients Admitted to an Emergency Department: An Italian Cohort Study
por: Di Micco, Pierpaolo, et al.
Publicado: (2020)

Postoperative decreased levels of D-dimer in patients with gynecologic cancer with enoxaparin and fondaparinux thromboprophylaxis
por: KODAMA, JUNICHI, et al.
Publicado: (2013)

Assay-Based Differentiation in the Neutralization Profile of Unfractionated Heparin, Enoxaparin, and Fondaparinux by Andexanet Alfa
por: Siddiqui, Fakiha, et al.
Publicado: (2020)

Clotting Factors in COVID-19: Epidemiological Association and Prognostic Values in Different Clinical Presentations in an Italian Cohort
por: Di Micco, Pierpaolo, et al.
Publicado: (2020)

Thromboembolic events and haematological diseases: a case of stroke as clinical onset of a paroxysmal nocturnal haemoglobinuria
por: Granata, Gianluca, et al.
Publicado: (2004)

Pathophysiology of Vaccine-Induced Prothrombotic Immune Thrombocytopenia (VIPIT) and Vaccine-Induced Thrombocytopenic Thrombosis (VITT) and Their Diagnostic Approach in Emergency
por: Di Micco, Pierpaolo, et al.
Publicado: (2021)

Fondaparinux versus Enoxaparin - Which is the Best Anticoagulant for Acute Coronary Syndrome? - Brazilian Registry Data
por: Soeiro, Alexandre de Matos, et al.
Publicado: (2016)

Enoxaparin-sodium/fondaparinux-sodium: Major and clinically relevant bleeding complications: 8 case reports
Publicado: (2020)

Fondaparinux vs. enoxaparin for the prevention of venous thromboembolism after total hip replacement: A meta-analysis
por: Dong, Wen-Jun, et al.
Publicado: (2016)

The hazard of fondaparinux in non-critically ill patients with COVID-19: Retrospective controlled study versus enoxaparin
por: Prandoni, Paolo, et al.
Publicado: (2020)

Cost-effectiveness of fondaparinux versus enoxaparin in non-ST-elevation acute coronary syndrome in Canada (OASIS-5)
por: Alfonso Ross Terres, Jorge, et al.
Publicado: (2015)

Choosing between Enoxaparin and Fondaparinux for the management of patients with acute coronary syndrome: A systematic review and meta-analysis
por: Bundhun, Pravesh Kumar, et al.
Publicado: (2017)

Venous Thromboembolism and Its Association with COVID-19: Still an Open Debate
por: Di Micco, Pierpaolo, et al.
Publicado: (2020)

The Fondaparinux Paradox: Fondaparinux-Related Heparin-induced Thrombocytopenia
por: Vadi, Sonali, et al.
Publicado: (2018)

Resolution of Disseminated Intravascular Coagulation in a Patient with COVID-19 and Associated Sepsis—Induced Neutropenia
por: Di Micco, Pierpaolo, et al.
Publicado: (2021)

Efficacy and safety of fondaparinux versus enoxaparin in patients undergoing percutaneous coronary intervention treated with the glycoprotein IIb/IIIa inhibitor tirofiban
por: Zhao, Xin, et al.
Publicado: (2016)

Idiopathic Hypereosinophilia and Venous Thromboembolism: Is There a Pathophysiological or Clinical Link? Description of an Intriguing Clinical Case
por: Di Micco, Pierpaolo, et al.
Publicado: (2020)

In vitro Fertilization Procedures with Embryo Transfer and Their Association with Thrombophilia, Thrombosis and Early Antithrombotic Treatments
por: Di Micco, Pierpaolo, et al.
Publicado: (2020)

Effectiveness and Tolerability of Fondaparinux vs Enoxaparin in a Population of Indian Patients with Symptomatic Deep Vein Thrombosis: A Retrospective Real-World Study
por: Ramakrishna, Pinjala, et al.
Publicado: (2021)

Fondaparinux-associated Thrombocytopenia
por: Malik, Jahanzeb, et al.
Publicado: (2021)

Clinical Differences between COVID-19 and a COVID-Like Syndrome
por: Di Micco, Pierpaolo, et al.
Publicado: (2021)

Correction: Di Micco et al. Clinical Differences between COVID-19 and a COVID-like Syndrome. J. Clin. Med. 2021, 10, 2519
por: Di Micco, Pierpaolo, et al.
Publicado: (2022)

Different outcome of six homozygotes for prothrombin A20210A gene variant
por: Di Micco, Pierpaolo, et al.
Publicado: (2008)

Hyperhomocysteinemia in women with unexplained sterility or recurrent early pregnancy loss from Southern Italy: a preliminary report
por: D'Uva, Maristella, et al.
Publicado: (2007)

Case report: Successful thromboprophylaxis with enoxaparin in a pregnant woman with internal jugular vein agenesis
por: Di Micco, Pierpaolo, et al.
Publicado: (2022)

When Will Fondaparinux Induce Thrombocytopenia?
por: Chen, Li-Yu, et al.
Publicado: (2022)

Design and Synthesis of Neutralizable Fondaparinux
por: Zhang, Liangwei, et al.
Publicado: (2022)

Utilizing enoxaparin in the management of STEMI
por: Rubboli, Andrea, et al.
Publicado: (2007)

Management of acute coronary syndromes with fondaparinux
por: Wienbergen, Harm, et al.
Publicado: (2007)

Thromboelastographic monitoring of fondaparinux in surgical patients
por: Martinez, B, et al.
Publicado: (2013)

Efficacy and safety of bivalirudin bridging enoxaparin versus fondaparinux in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: evidence from a single-center study
por: Guo, Yanqing, et al.
Publicado: (2023)

Is there a relationship between factor V Leiden and type 2 diabetes?
por: Lodigiani, Corrado, et al.
Publicado: (2009)

Anticoagulant therapy with fondaparinux in a liver transplant patient with thrombosis and liver fibrosis: a case report
por: Cafolla, Arturo, et al.
Publicado: (2017)

Failure of Fondaparinux in Autoimmune Heparin-Induced Thrombocytopenia
por: Sartori, Michelangelo, et al.
Publicado: (2020)

Probable fondaparinux-associated bullous hemorrhagic dermatosis
por: Lovatt, Catherine Anne, et al.
Publicado: (2021)

Differences in the INR evaluation of two different thromboplastins in patients with positivity to lupus anticoagulant in ongoing oral anticoagulation
por: Ferrazzi, Paola, et al.
Publicado: (2010)

Clinical impact of pre-admission antithrombotic therapy in hospitalized patients with COVID-19: A multicenter observational study
por: Russo, Vincenzo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_la65d4vql60spip800gdp36vsm